Response to: Note the distinction between myocarditis, novel coronavirus myocarditis and COVID-19 vaccine-associated myocarditis.

Awaya, T; Koizumi, T; Enomoto, Y; Moroi, M; Nakamura, M

Awaya, T; Koizumi, T; Enomoto, Y; Moroi, M; Nakamura, M.

Afiliação

Awaya T; From the Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Koizumi T; From the Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Enomoto Y; From the Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Moroi M; From the Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Nakamura M; From the Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.

QJM ; 115(10): 696, 2022 10 25.

Article em En | MEDLINE | ID: mdl-34791457

Assuntos

COVID-19; Miocardite; Humanos; Vacinas contra COVID-19/efeitos adversos; Miocardite/induzido quimicamente; Miocardite/diagnóstico; SARS-CoV-2

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Miocardite Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: QJM Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google